AI assistant
Sending…
BeOne Medicines Ltd. — Director's Dealing 2022
Jun 21, 2022
30073_dirs_2022-06-21_b40056a2-34cf-44ee-b081-b4c4cabf0212.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2022-06-17
Reporting Person: Wang Julia Aijun (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-06-17 | American Depositary Shares | S | 161 | $136.6393 | Disposed | 0 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 141206 | Direct |
Footnotes
F1: Each American Depositary Share represents 13 Ordinary Shares.
F2: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
More from BeOne Medicines Ltd.
Regulatory Filings
2026
May 15
Regulatory Filings
2026
May 6
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Annual Report
2026
Apr 28
Proxy Solicitation & Information Statement
2026
Apr 28
Regulatory Filings
2026
Apr 14
Annual Report
2026
Feb 26
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 6